HIV/HCV Co-infection: Overcoming Barriers to Treatment

详细信息    查看全文

• 作者：Chloe Gross ; RN ; BSN ; ACRN ; ^{chloe.gross@nih.gov" class="auth_mail" title="E-mail the corresponding author}Author Vitae ; Elizabeth Akoth ; RN ; BSN ; MSNAuthor Vitae ; Angie Price ; MSN ; CRNPAuthor Vitae ; Sarah Kattakuzhy ; MDAuthor Vitae ; Rachel Silk ; RN ; BSN ; MPHAuthor Vitae ; Elana Rosenthal ; MDAuthor Vitae
• 关键词：direct-acting antivirals ; HCV ; HIV ; managed care organizations ; sustained virologic response ; underserved population
• 刊名：Journal of the Association of Nurses in AIDS Care
• 出版年：2016
• 出版时间：July-August 2016
• 年：2016
• 卷：27
• 期：4
• 页码：524-529
• 全文大小：601 K

文摘

A critical step in the eradication of hepatitis C virus (HCV) infection is access to effective therapy. With the advent of interferon-free regimens, HCV providers and patients gained hope that the success seen in clinical trials could be translated to the real world. However, the exorbitant cost of the new direct-acting antivirals limits access to these medications to the general HCV population, especially underserved patients with public insurance. We used a descriptive qualitative approach to detail the measures necessary and challenges faced by an inner-city nursing team in Washington, DC to obtain the new direct-acting antivirals. Significant time and dedication on the part of providers and staff was required to assist patients with the process of obtaining direct-acting antivirals.